Pharmaco-EEG: From cellular to the network level. EEGβ spectral power as a biomarker for GABAergic inhibition and its role in the assessment of AEDs

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 24, Issue SUPPL. D, 2002, Pages 3-

  Lopes da Silva, F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; BENZODIAZEPINE; BIOLOGICAL MARKER;

ANIMAL MODEL; ANTICONVULSANT THERAPY; CONFERENCE PAPER; DRUG TARGETING; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTOGENESIS; HUMAN; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; SEIZURE; ANIMAL; ARTICLE; DRUG EFFECT; METHODOLOGY; NERVE CELL INHIBITION; PHARMACEUTICS; PHYSIOLOGY;

ANIMALS; ANTICONVULSANTS; BIOLOGICAL MARKERS; ELECTROENCEPHALOGRAPHY; HUMANS; NEURAL INHIBITION; RECEPTORS, GABA; TECHNOLOGY, PHARMACEUTICAL;

EID: 1842843335     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Mandema, J.W., Samson, L.N., Dios-Vietz, M.C., Hollander-Janse, M., Danhof, M. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 1991, 257: 472-8.
2. Cleton, A., Altorf, B.A., Voskuyl, R.A. Danhof, M. Pharmacokinetic-pharmacodynamic modelling of tiagabine CNS effects upon chronic treatment in rats: Lack of change in concentration-EEG effect relationship. Eur J Pharm Sci 2000, 12: 141-50.
3. Cleton, A., Altorf, B.A., Voskuyl, R.A., Danhof, M. Effect of amygdata kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels. Br J Pharmacol 2000, 130: 1037-44.
4. Voskuyl, R.A., Jonker, D.M., Lopes da Silva, F.H. Future research an experimental perspective. In: Antiepileptic Drugs - Combination Therapy and Interactions. J. Majkowski, B.F.D. Bourgeois, P.N. Paslaos, R.H. Mattson (Eds.). 2002 (In press).